56. ベーチェット病 Behcet disease Clinical trials / Disease details


臨床試験数 : 76 薬物数 : 110 - (DrugBank : 32) / 標的遺伝子数 : 36 - 標的パスウェイ数 : 116

  
5 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR2100045463
2021-05-012021-04-15Efficacy and safety of Adalimumab in refractory intestinal Behcet’s disease: A single-center, interventional, open-label, single-arm studyEfficacy and safety of Adalimumab in refractory intestinal Behcet’s disease: A single-center, interventional, open-label, single-arm study intestinal Beh?et's diseaseOne-armed intervention group:adalimumab;The First Affiliated Hospital, College of Medicine, Zhejiang UniversityNULLRecruiting1870BothOne-armed intervention group:30;Phase 4China
2ChiCTR1900027147
2020-01-012019-11-02Efficacy and safety of adalimumab in Behcet's disease-related uveitisEfficacy and safety of adalimumab in Behcet's disease-related uveitis Behcet's disease-related uveitis1:Adalimumab;State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen UniversityNULLPendingBoth1:30;Phase 4China
3EUCTR2017-000845-39-IT
(EUCTR)
12/05/201708/06/2021Effectiveness of anti TNFalpha agents in Behcet¿s diseaseTHE ROLE OF ANTI TNF ALPHA AGENTS IN BEH¿ET¿S DISEASE REFRACTORY TO STANDARD OF CARE THERAPIES: MULTICENTER RANDOMIZED CONTROLLED PROSPECTIVE PARALLEL GROUP SINGLE-BLIND TRIAL TO EVALUATE THE 6 MONTH EFFECTIVENESS OF EITHER INFLIXIMAB OR ADALIMUMAB - FARM12LTAT BEH¿ET¿S DISEASE REFRACTORY TO STANDARD OF CARE THERAPIES
MedDRA version: 20.0;Level: LLT;Classification code 10004215;Term: Behcets disease;System Organ Class: 100000004866;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Trade Name: HUMIRA - 40 MG SOLUZIONE INIETTABILE USO SOTTOCUTANEO 1 SIRINGA PRERIEMPITA 0.8 ML + 1 TAMPONE IMBEVUTO DI ALCOL IN UN BLISTER
Product Name: HUMIRA
Product Code: HUMIRA
INN or Proposed INN: ADALIMUMAB
Trade Name: INFLECTRA - 100 MG - POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) - 1 FLACONCINO
Product Name: INFLECTRA
Product Code: INFLECTRA
INN or Proposed INN: INFLIXIMAB
Trade Name: MEDROL - 4 MG COMPRESSE 30 COMPRESSE
Product Name: MEDROL
INN or Proposed INN: METILPREDNISOLONE
Trade Name: SOLU MEDROL - 500 MG/8 ML POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 1 FLACONE DI POLVERE DA 500 MG+ FIALA SOLVENTE DA 8 ML
Product Name: SOLU MEDROL
Product Code: SOLU MEDROL
INN or Proposed INN: METILPREDNISOLONE SODIO SUCCINATO
Trade Name: SOLU MEDROL - 40 MG/ML POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 1 FLACONE A DOPPIA CAMERA DA 40 MG/ML
Product Name: SOLU MEDROL
Product Code: SOLU MEDROL
AZIENDA OSPEDALIERO-UNIVERSITARIA PISANANULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
46Phase 3Italy
4JPRN-UMIN000012469
2013/12/0202/12/2013Comparison of Adalimumab and Steroid in Intestinal Behcet's diseaseComparison of Adalimumab and Steroid in Intestinal Behcet's disease - Castle Study Intestinal Behcet's diseaseSubcutaneous injection of adalumumab with 160mg at 0 week, 80mg at 2 weeks and 40mg every other week after at 4 weeks continuously.
Oral administration of prednisolone with 0.6mg/kg/day during from 1 to 2 weeks, and tapering off until 12 weeks with decreasing dosage 5mg/kg/week approximately
Castle Study GroupNULLRecruiting15years-oldNot applicableMale and Female50Not selectedJapan
5NCT01243671
(ClinicalTrials.gov)
October 201017/11/2010A Study of Adalimumab in Japanese Subjects With Intestinal Behçet's DiseaseA Multi-Center Study of Adalimumab in Japanese Subjects With Intestinal Behçet's DiseaseIntestinal Behçet's DiseaseBiological: AdalimumabAbbVie (prior sponsor, Abbott)Eisai Co., Ltd.Completed15 YearsN/AAll20Phase 3Japan